Vyne Therapeutics Company Insiders
VYNE Stock | USD 2.96 0.01 0.34% |
Vyne Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Vyne Therapeutics suggests that all insiders are extremely bullish. Vyne Therapeutics employs about 10 people. The company is managed by 11 executives with a total tenure of roughly 24 years, averaging almost 2.0 years of service per executive, having 0.91 employees per reported executive.
Vyne Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2023-11-15 | Patrick G Lepore | Acquired 13000 @ 3.91 | View | ||
2023-03-20 | Patrick G Lepore | Acquired 20000 @ 2.48 | View | ||
2021-11-30 | Patrick G Lepore | Acquired 694 @ 18.36 | View |
Monitoring Vyne Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Vyne |
Vyne Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Vyne Therapeutics' future performance. Based on our forecasts, it is anticipated that Vyne will maintain a workforce of about 30 employees by December 2024.Vyne Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3454) % which means that it has lost $0.3454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6047) %, meaning that it created substantial loss on money invested by shareholders. Vyne Therapeutics' management efficiency ratios could be used to measure how well Vyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.34. At present, Vyne Therapeutics' Net Tangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Current Assets are forecasted to decline to about 78.4 M.The current year's Common Stock Shares Outstanding is expected to grow to about 10.8 M, whereas Net Loss is forecasted to decline to (21.9 M).
Vyne Therapeutics Workforce Comparison
Vyne Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,457. Vyne Therapeutics maintains roughly 10.0 in number of employees contributing less than 1% to equities under Health Care industry.
Vyne Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vyne Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 0.25 | 1 | 4 | 4,429 | 1,416 |
2024-03-01 | 3.5 | 14 | 4 | 965,000 | 1,415 |
2023-12-01 | 2.5 | 15 | 6 | 940,284 | 7,804,422 |
2023-06-01 | 0.5 | 2 | 4 | 6,430 | 1,380 |
2023-03-01 | 0.5 | 2 | 4 | 30,000 | 4,076 |
2022-12-01 | 0.25 | 1 | 4 | 34,705 | 14,572 |
2022-09-01 | 2.25 | 9 | 4 | 184,500 | 14,568 |
2022-06-01 | 0.5 | 2 | 4 | 24,397 | 14,569 |
2022-03-01 | 2.25 | 9 | 4 | 1,149,605 | 31,058 |
2021-12-01 | 0.75 | 3 | 4 | 21,392 | 9,827 |
2021-09-01 | 2.1429 | 15 | 7 | 1,141,282 | 855,163 |
2021-06-01 | 0.2727 | 3 | 11 | 16,458 | 1,077,432 |
2021-03-01 | 2.4 | 12 | 5 | 5,128,784 | 13,361 |
2020-12-01 | 1.0 | 4 | 4 | 72,561 | 15,397 |
2020-09-01 | 1.8 | 9 | 5 | 347,500 | 86,980 |
2020-06-01 | 3.125 | 25 | 8 | 6,621,675 | 32,897 |
2020-03-01 | 4.6154 | 60 | 13 | 2,850,666 | 8,609 |
2019-12-01 | 0.6429 | 9 | 14 | 850,890 | 980,045 |
2019-03-01 | 1.0 | 1 | 1 | 33,355 | 25,000 |
2018-06-01 | 1.5 | 3 | 2 | 340,850 | 180,092 |
2018-03-01 | 0.8438 | 27 | 32 | 13,037,714 | 15,385,071 |
Vyne Therapeutics Notable Stakeholders
A Vyne Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vyne Therapeutics often face trade-offs trying to please all of them. Vyne Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vyne Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Domzalski | President CEO | Profile | |
Tyler CPA | CFO Treasurer | Profile | |
Russell DPhil | VP Devel | Profile | |
Iain Stuart | Chief Officer | Profile | |
MS MD | Consultant | Profile | |
Subhashis MD | Senior Development | Profile | |
David Schuz | VP Property | Profile | |
Faad MD | Consultant | Profile | |
Tyler Zeronda | Principal CFO | Profile | |
MD FAAD | Consultant | Profile | |
Mutya JD | Chief Counsel | Profile |
About Vyne Therapeutics Management Performance
The success or failure of an entity such as Vyne Therapeutics often depends on how effective the management is. Vyne Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vyne management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vyne management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.29) | (0.31) | |
Return On Capital Employed | (0.32) | (0.34) | |
Return On Assets | (0.29) | (0.31) | |
Return On Equity | (0.32) | (0.34) |
Please note, the presentation of Vyne Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vyne Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vyne Therapeutics' management manipulating its earnings.
Vyne Therapeutics Workforce Analysis
Traditionally, organizations such as Vyne Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vyne Therapeutics within its industry.Vyne Therapeutics Manpower Efficiency
Return on Vyne Therapeutics Manpower
Revenue Per Employee | 42.4K | |
Revenue Per Executive | 38.5K | |
Net Loss Per Employee | 2.8M | |
Net Loss Per Executive | 2.6M | |
Working Capital Per Employee | 8.8M | |
Working Capital Per Executive | 8M |
Complementary Tools for Vyne Stock analysis
When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |